UroGen Pharma Ltd. (URGN) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High margins ⢠Heavy cash burn ⢠Negative equity URGN combines strong gross margins and adequate near-term liquidity with severe operating losses, heavy cash burn, and a highly leveraged, negative-equity balance sheet.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support hold ⢠Momentum faded Support Level: $26.5-$26.6 Resistance Level: $28.7-$29.5 URGN is flat over the last month overall, but the chart has rolled over into a short-term downtrend with lower highs and lower lows, leaving $26.5-$26.6 as key support and $28.7-$29.5 as initial resistance.
Sentiment & News
Key News Insights: ⢠Sales Momentum ⢠Trial Progress ⢠Patent Protection URGN's news flow was broadly positive, driven by strong ZUSDURI sales growth, encouraging trial results, and patent protection that supports its near-term commercialization and long-term value story.
AI Summary
URGN has shifted from a purely binary biotech story to a real commercial execution case with strong revenue and 91%-92% gross margins, but investors should focus on whether ZUSDURI/JELMYTO growth can outrun persistent cash burn, rising debt, and eventual generic pressure before the current valuation can re-rate.
Description
UroGen Pharma Ltd. is a biotechnology company developing treatments for urothelial diseases and specialty cancers, using a biocompatible reverse thermal gel platform to modify drug delivery and exposure. Its pipeline includes UGN-102, currently in Phase III for several forms of non-muscle invasive urothelial cancer, and UGN-301 for high-grade disease, alongside a commercial offering based on its hydrogel technology. The company maintains licensing and development agreements with Allergan and Agenus and a research collaboration with MD Anderson, and is based in Princeton, New Jersey (incorporated 2004).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | URGN | UroGen Pharma Ltd. | UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points. | Closed | +22.3% |